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Abstract: Communication is critical for all aspects of public health. In the pharmaceutical industry, the patient package insert is used to 
relay important information to patients. Unfortunately, there are intrinsic flaws with the current patient package insert that can be seen 
through the vast number of medical injuries patients incur. This article dissects the root problems of the patient package insert in the 
modern world and analyzes the utilization of infographics to combat these issues. 
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n a constantly changing world, the only way to thrive is to 
adapt to new norms. Adaptation applies to all aspects of soci-
ety: education, employment, entertainment, public health, and 
safety. Despite diminished attention spans being one of the 
major changes in today’s world, there is a lack of response in the 
public health safety sector. For decades, the U.S. Food and Drug 
Administration (FDA) has administered long, detailed Patient 
Package Inserts (PPIs) with prescription drugs. These PPIs con-
tain a plethora of crucial information for patients’ safety, includ-
ing warnings, precautions, adverse reactions, and drug interac-
tions. Additionally, PPIs provide background information about 
the drug itself, which can be seen in the clinical studies, descrip-
tion, and clinical pharmacology sections. With people’s dimin-
ishing ability to focus their attention, crucial information may be 
overlooked or ignored. A revolution in public communication is 
pertinent for maintaining safety in the realm of public health.  
 
THE PROBLEM: COMMUNICATION 
Not all communication styles are created equal, and 
public communication is unique in its topics and target audi-
ence. Public communication consists of a group, like the FDA, 
communicating with the general public1; PPIs are an example of 
this modality. There are a few key characteristics that embody all 
public communications: large scale distribution and reception, 
heterogeneous audience, impersonal interactions, and an asym-
metrical sender-receiver relationship.1 Unfortunately, these 
commonalities make public communication difficult. In other 
words, public communication is distributed to the masses, who 
lack a unifying trait outside of geographical location, eg, the 
United States. It is also one-sided since there is no face-to-face 
interaction, and the receiver is not able to ask for clarification. 
The diverse target-audience makes the word choice challenging 
because not all members of the population have the same edu-
cational background, yet they must be able to comprehend the 
message to the same degree. Furthermore, the asymmetrical 
relationship between sender and receiver presents an additional 
challenge because impersonal communication makes it more 
difficult for the recipient to receive the correct message.  
Within pharmacy, public communication can be seen in 
a few different areas. Firstly, the FDA can require drug studies of 
prescription drugs after they are approved for marketing. The 
FDA can also require a risk evaluation and mitigation strategy 
(REMS) for potentially dangerous drugs. While REMS may be re-
quired in order to gain initial FDA approval, the FDA can also 
require REMS to be added to already marketed drugs to help 
share important safety discoveries with healthcare profession-
als.2 Patients may also receive documentation via medication 
guides and PPIs based on the additional data gathered when a 
drug is widely used.2 Secondly, and perhaps more noticeably, 
public communication can be seen with product labelling and 
patient package inserts. The pharmaceutical industry has greatly 
relied on these two tools to inform patients of health risks since 
the 1960s.3  
 Although the PPI is standard today, it was not unani-
mously accepted when it was first brought to the public. In the 
1970s, the FDA considered requiring the accompaniment of a 
PPI with all oral contraceptive pills.4 Both physicians and phar-
maceutical companies opposed the idea based on the notion 
that it would interfere with the doctor-patient relationship.4 Prior 
to 1970s, the physician normally controlled both the patient’s 
treatment and how well the patient understood his or her treat-
ment plan.4 This provided physicians with supreme power and 
allowed manufacturers and physicians to foster strong relation-
ships with each other.4 Because of the potential lack of under-
standing by patients, the FDA began requiring PPIs. Charles F. 
Keown stated that PPIs would,  
promote patient understanding and adher-
ence to drug therapy, permit the patient to 
avoid adverse interactions with other drugs or 
foods, prepare the patient for possible side 
effects, and permit the patient to share in the 
decision to use the drug.5  
Furthermore, historian Elizabeth Watkins stated that, “in the ab-
sence of good doctor-patient communication…, the insert would 
supply facts necessary to make an informed choice.”4 These 
goals are accurate and desirable, but they are not always easy to 
achieve with PPIs alone. 
 Historically, PPIs have effectively relayed important in-
formation about specific drugs. Patient package inserts attempt 
to address adverse reactions, both serious and mild, to improve 
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safety of the general public. Knowledge of the existence and fre-
quency of adverse drug events is essential in establishing drug 
safety.6 One might think PPIs are working beautifully and do not 
require tweaking since their major goal coincides with one of the 
most import aspects of public health safety. However, PPIs may 
not be as effective as desired.  
Dr Brian Edwards and Dr Sweta Chakraborty explained 
that each individual’s perception influences public reception and 
processing of risk communications.3 From this, we can under-
stand that although creators of PPIs have the right goals in mind, 
their pamphlets may not convey the proper message to the gen-
eral public. Moreover, patients are unable to identify the most 
crucial of warnings from the PPI. This is evident when observing 
that hospital admissions for all medication and drug related 
issues have increased by 117% from 1997 to 2008.3 This statistic 
is the greatest indication that our patient package inserts are not 
adapting to modern times and therefore require modification. 
Any modification should address the lack of user-friendliness 
and eliminate as much confusion as possible throughout the 
entire population. It must ensure that all patient groups can uti-
lize every PPI in order to establish universal drug safety.  
 
THE POSSIBLE SOLUTION: THE INFOGRAPHIC 
Perhaps the easiest way to account for heterogeneity 
of the population is by utilizing infographics to convey the most 
crucial information to patients. Infographics are a perfect avenue 
for communicating to an educationally diverse population due 
to the use of visual aids. Visual aids can provide a more universal 
language in order to help people understand a foreign term or 
the severity of a symptom of an adverse effect. For example, a 
patient may not understand a warning for tachycardia, a dan-
gerously rapid heart rate, but he or she may better comprehend 
a skull placed beside a vertical “up” arrow graphic in front of a 
heart with an embedded EKG reading. Visual aids also allow for 
the creation of context, as well as improvements on the passive 
voice frequently seen in PPIs that can be difficult to understand.  
Infographics are the ideal solution to our society’s de-
creasing attention span because they exploit visual processing, 
which is the most dominant capacity of the human brain.7 This 
function is integral for learning, therefore infographics can relay 
more information over a shorter duration of time.7 Furthermore, 
the structure of infographics allows information to be portrayed 
as a story, which utilizes our most evolutionarily-conserved pro-
cess of understanding.7 The use of colors in infographics can also 
add to comprehension and help those that have impaired vision 
or memory, eg, Alzheimer’s disease patients.8 For example, 
elderly patients tend to have weaker vision so utilizing red print 
with a yellow background greatly increases their ability to read.8 
One could also use violets and soft yellows for medications that 
should be taken with food because these colors tend to increase 
one’s appetite.8  
Infographics do a tremendous job relaying information 
in an easy-to-understand format via data-visualization, but they 
have limitations. It is important not to include more than 5 main 
points of interest in an infographic, as anything more will likely 
result in a lengthy infographic. As the length increases, people’s 
declining attention spans will interfere with comprehension. 
Therefore, compressing all of the information from a PPI into a 
single infographic may result in oversimplification, which would 
limit a patient’s understanding of his or her new medicine.  
In conclusion, patient package inserts cannot be re-
placed by infographics, but PPIs should be accompanied by 
them. Infographics could drastically help with Black Box Warn-
ings and other sections laden with medical jargon due to their 
incorporation of visual aids. Pictographs are a universal 
language across populations because they provide multiple in-
puts to our brain and eliminate many of the barriers of public 
communication. Research does not yet exist for the effectiveness 
of patient education infographics, but there is potential benefit 
of infographics in every patient population.  
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